Clostridia in cancer therapy

Nature Reviews Microbiology

Volumn 1, Issue 3, 2003, Pages 237-242

  Minton, Nigel P ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; 5-(1-AZIRIDINYL)-2,4-DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; CYTOSINE DEAMINASE; NITROREDUCTASE; PRODRUG; XANTHONE DERIVATIVE;

ANIMAL; BACTERIAL SPORE; CARCINOMA; CLOSTRIDIUM; DRUG DELIVERY SYSTEM; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METHODOLOGY; MICROBIOLOGY; MOUSE; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CARCINOMA; CLOSTRIDIUM; CYTOSINE DEAMINASE; DRUG DELIVERY SYSTEMS; HUMANS; MICE; NEOPLASMS; NITROREDUCTASES; PRODRUGS; SPORES, BACTERIAL; XANTHONES;

EID: 1842613536     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro777     Document Type: Article

References (51)

1. Bagshawe, K. D. Antibody directed enzymes revive anti- cancer prodrug concept. Br. J. Cancer 56, 531-532 (1987).
2. Dobbelstein, M. Viruses in therapy — royal road or dead end? Virus Res. 92, 219-221 (2003).
3. St George, J. A. Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 10, 1135-1141 (2003).
4. Krasnykh, V. et al. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res. 60, 6784-6787 (2000).
5. Alemany, R., Balague, C. & Curiel, D. T. Replicative adenoviruses in cancer therapy. Nature Biotechnol. 18, 723-727 (2000).
6. Connolly, J. B. Conditionally replicating viruses in cancer therapy. Gene Ther 10, 712-715 (2003).
7. Reddy, J. A. et al. Folate-targeted, cationic liposome- mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 9, 1542-1550 (2002).
8. Ogris, M. et al. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol- polyethylenimine/DNA complexes. J. Control. Release 91, 173-181 (2003).
9. De Palma, M., Venneri, M. A. & Naldini, L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum. Gene Ther. 14, 1193-1206 (2003).
10. Greco, O. et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther. 20, 1403-1411 (2002).
11. Smrekar, B. et al. Tissue-dependent factors affect gene delivery to tumors in vivo. Gene Ther. 10, 1079-1088 (2003).
12. 2 homeostasis. Curr. Opin. Genet. Dev. 8, 588-594 (1998).
13. Binley, K. et al. Hypoxia-mediated tumour targeting. Gene Ther. 10, 540-549 (2003).
14. Harris, A. L. Hypoxia — a key regulatory factor in tumour growth. Nature Rev. Cancer 1, 38-47 (2002).
15. Minton, N. P, Brown, J. M., Lambin, P & Anne, J. in Clostridia — Biotechnology and Medical Applications. (eds Bahl, H. & DUrre, P) 251-270 (Wiley, Weinheim, 2001).
16. Parker, R. C., Plumber, H. C., Siebenmann, C. O. & Chapman, M. G. Effect of histolyticus infection and toxin on transplantable mouse tumours. Proc. Soc. Exp. Biol. Med. 66, 461-465 (1947).
17. Malmgren, R. A. & Flanigan, C. C. Localization of the vegetative form of Clostridium tetaniin mouse tumours following intravenous spore administration. Cancer Res. 15, 473-478 (1955).
18. Theys, J. et al. Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor a. Appl. Environ. Microbiol. 65, 4295-4300 (1999).
19. Theys, J. et al. Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect. Prevent. 25, 548-557 (2001).
20. Francis, R. J. et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br. J. Cancer 87, 600-607 (2002).
21. Spooner, R. A. et al. A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. Br. J. Cancer 88, 1622-1630 (2003).
22. Niculescu-Duvaz, I., Spooner, R., Marais, R. & Springer, C. J. Gene-directed enzyme prodrug therapy. Bioconjug. Chem. 9, 4-22 (1998).
23. Green, N. K. et al. Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int. J. Cancer 104, 104-112 (2003).
24. Okabe, S., Arai, T., Yamashita, H. & Sugihara, K. Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells. J. Cancer Res. Clin. Oncol. 129, 367-373 (2003).
25. Xu, G. & McLeod, H. L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 7, 3314-3324 (2001).
26. Minton, N. P. et al. Chemotherapeutic tumour targeting using clostridial spores. FEMS Mlcroblol. Rev. 17, 357-364 (1995).
27. 14C in mouse, rat, rabbit, dog and man. Chemotherapy 22, 137-153 (1976).
28. Anlezark, G. M. et al. The bioactivation of 5-(aziridin-1- y1)-2, 4-dinitrobenzamide (CB1954). I. Purification and properties of a nitroreductase enzyme from Escherichia coll: a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 44, 2289-2295 (1992).
29. Mauchline, M. L., Davis, T. O. & Minton, N. P. in Manual of Industrial Microbiology and Biotechnology, 2nd Edition (eds Demain, A. L. & Davies, J. E.) 475-490 (Washington DC, ASM Press, 1999).
30. Lemmon, M. J. et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 4, 791-796 (1997).
31. Lam bin, P. et al. Colonisation of the Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe 4, 183-188 (1998).
32. Fox, M. E. et al. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5- fluorocytosine by genetically engineered Clostridia. Gene Ther. 3, 173-178 (1996).
33. Theys, J. et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutyllcum. Cancer Gene Ther. 8, 294-297 (2001).
34. Liu, S. C., Minton, N. P., Giaccia, A. J. & Brown, M. J. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 9, 291-296 (2002).
35. Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W. & Vogelstein, B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl Acad. Sci. USA 98, 15155-15160 (2001).
36. Nuyts, S. et al. The use of radiation-induced bacterial promoters in anaerobic conditions: a means to control gene expression in clostridium-mediated therapy for cancer. Radiat. Res. 155, 716-723 (2001).
37. Nuyts, S. et al. Radio-responsive recA promoter significantly increases TNFa production in recombinant clostridia after 2 Gy irradiation. Gene Ther. 8, 1197-1201 (2001).
38. Nuyts, S. et al. Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters. Appl. Environ. Microbiol. 67, 4464-4470 (2001).
39. Jorgensen, H. & Overgaard, J. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv. Exp. Med. Biol. 476, 311-323 (2000).
40. Theys, J. et al. Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol. Med. Microbiol. 30, 37-41 (2001).
41. Liu, S. C. et al. Tumour-specific enzyme/prodrug gene therapy using genetically engineered C. sporogenes as a delivery system combined with vascular-targeting agents. Fourth International Conference on the Molecular Biology and Pathogenesis of the Clostridia, Woods Hole, Massachusetts (2003).
42. Fujimori, M., Amano, J. & Taniguchi, S. The genus Bifidobacterium for cancer gene therapy. Curr. Opin. Drug Discov Devel. 5, 200-203 (2002).
43. Grove, J. I. et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res. 63, 5532-5537 (2003).
44. Anlezark, G. M. et al. The Bacillus amyloliquefaciens orthologue of B. subtilisywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954. Microbiology 148, 297-306 (2002).
45. Spencer, D. I. R. et al. A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomlcs 3, 271-279 (2002).
46. Pawelek, J. M., Low, K. B. & Bermudes, D. Tumor- targeted Salmonella as a novel anticancer vector. Cancer Res. 57, 4537-4544 (1997).
47. Low, K. B. et al. Lipid A mutant Salmonella with suppressed virulence and TNFa induction retain tumor- targeting in vivo. Nature Blotechnol. 17, 37-41 (1999).
48. Toso, J. F. et al. Phase I study of the intravenous administration of attenuated Salmonella typhlmurlum to patients with metastatic melanoma. J. Clin. Oncol. 20, 142-152 (2002).
49. Zheng, L. M. et al. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol. Res. 12, 127-135 (2000).
50. Yazawa, K., Fujimori, M., Amano, J., Kano, Y. & Taniguchi, S. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther. 7, 269-274 (2000).
51. Li, X. et al. Bifidobacterium adolescentls as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 10, 105-111 (2003).